

Supplier Name: SyriMed Ltd
Publication Date 27/02/2026

SyriMed Corporate Social Value Programme

1. Statement of Commitment

SyriMed is committed to delivering social value through responsible pharmaceutical supply, ethical supply chain management, environmental sustainability, and workforce wellbeing. We aim to provide patients with consistent access to safe, high-quality medicines, offer clinicians reliable supply partnerships with fewer disruptions, and help communities achieve better health outcomes and reduced environmental impact.

As an NHS supplier, we support the NHS Net Zero ambition and integrate sustainability and responsible governance into our operations.

This Corporate Social Value Programme provides the framework for SyriMed to deliver measurable social, environmental, and economic value.

2. Governance & Oversight

- Social Value oversight is managed at the Director level
- We review progress annually alongside Carbon Reduction Plan reporting
- We include sustainability and resilience in business planning

This programme aligns with SyriMed's PPN 06/21-compliant Carbon Reduction Plan, establishing a baseline year and staged emissions reduction targets.

3. Social Value Pillars

Pillar 1: Environmental Sustainability

SyriMed's Carbon Reduction Plan sets a baseline year (2025 with total emissions of 272,986.36 kg CO₂e) and a defined reduction trajectory. We measure each reduction target against this baseline to ensure transparent progress:

- A 50% interim reduction target, equating to annual emissions of 136,493.18 kg CO₂e by 2030
- A 75% reduction milestone by 2040, reducing emissions to 68,246.59 kg CO₂e
- Net Zero commitment by 2045, targeting zero residual emissions

We review progress annually using GHG Protocol and UK Government conversion factors.

Operational Actions Supporting These Targets:

- Structured monthly demand forecasting and variance analysis
- Two-month hospital safety stock thresholds to reduce stock-outs and waste
- Ringfencing NHS-dedicated volumes during API changes
- Proactive manufacturing planning to reduce emergency production
- Packaging optimisation initiatives
- Ongoing Scope 3 visibility improvements

By reducing reactive production and urgent logistics, SyriMed lowers carbon impact while maintaining supply resilience.

Pillar 2: Ethical & Responsible Supply Chain

SyriMed maintains a zero-tolerance policy toward modern slavery and unethical practices. We track and report human-rights indicators, including the percentage of suppliers completing independent ethical audits such as SMETA and the number of annual modern slavery compliance verifications. These indicators make our commitment measurable.

We:

- Maintain supplier qualification aligned to GMP/GDP requirements
- Embed compliance expectations within quality and technical agreements
- Review supplier policies and environmental practices
- Engage manufacturing and API partners to support improved planning and reduced waste

Through proactive supplier collaboration, we enhance transparency and responsible sourcing.

Pillar 3: Economic & Public Value Contribution

As a supplier under NHS frameworks, including NHS National Generic Orals Wave 14c, SyriMed contributes to public value by:

- Ensuring continuity of essential medicines
- Reducing risk of shortages through structured stock allocation
- Avoiding unnecessary waste through balanced production planning
- Supporting predictable supply patterns that reduce emergency activity

Reliable supply of essential medicines delivers direct public benefit through improved patient outcomes and operational efficiency.

Pillar 4: Workforce & Internal Responsibility

SyriMed is committed to:

Providing ongoing workforce learning to embed sustainability awareness, including hosting quarterly ESG lunch-and-learn sessions for employees.

- Fair employment practices
- Safe and compliant working environments
- Embedding sustainability awareness within operational decision-making
- Promoting ethical culture and whistleblowing transparency

We plan to expand internal sustainability awareness and enhance ESG reporting maturity.

SyriMed will:

- Review Social Value performance annually.
- Align reporting with Carbon Reduction Plan updates.
- Monitor key indicators such as:
 - Forecast accuracy and demand variance
 - Avoided emergency manufacturing events
 - Packaging optimisation initiatives

- Supplier engagement activity
- Scope 3 data visibility improvements

This programme will evolve as our sustainability and NHS requirements advance.

Declaration and Sign-Off

This programme has been reviewed and signed off by the Board of Directors.

Signed on behalf of SyriMed Limited:

Name: Declan Glavin

Position: Chief Operations Officer

Date: 03/03/2026

Signature:

A handwritten signature in black ink, appearing to be 'D Glavin', written over a horizontal line.